Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Multicenter Multicohort Open-label Phase II Trial Aiming to Define Optimal Methods for Predicting Response/Resistance to Antibody-drug Conjugates in Patients With Solid Tumors Treated According to Current Standard Indications.

NCT07259226 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT07259226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07259226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Multicenter Multicohort Open-label Phase II Trial Aiming to Define Optimal Methods for Predicting Response/Resistance to Antibody-drug Conjugates in Patients With Solid Tumors Treated According to Current Standard Indications.
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
November 14, 2025
Completion date
November 1, 2030
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced gastric cancer, advanced non small cell lung cancer (nsclc), advanced urothelial cancer